Axxcess Wealth Management LLC Acquires 386,964 Shares of Abbott Laboratories $ABT

Axxcess Wealth Management LLC raised its position in Abbott Laboratories (NYSE:ABT) by 276.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 526,962 shares of the healthcare product maker’s stock after acquiring an additional 386,964 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Abbott Laboratories were worth $66,023,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Abbott Laboratories by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock worth $21,995,501,000 after purchasing an additional 2,402,408 shares during the last quarter. Capital International Investors increased its stake in shares of Abbott Laboratories by 2.5% during the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after purchasing an additional 1,478,076 shares during the last quarter. Invesco Ltd. increased its stake in shares of Abbott Laboratories by 51.0% during the 3rd quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock worth $1,868,718,000 after purchasing an additional 4,713,135 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Abbott Laboratories by 3.8% during the 3rd quarter. Ameriprise Financial Inc. now owns 13,500,829 shares of the healthcare product maker’s stock worth $1,804,050,000 after purchasing an additional 499,351 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Abbott Laboratories by 7.2% during the 3rd quarter. Legal & General Group Plc now owns 12,900,318 shares of the healthcare product maker’s stock worth $1,727,869,000 after purchasing an additional 864,531 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at $12,053,953.78. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Philip P. Boudreau purchased 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was bought at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders sold 3,055 shares of company stock worth $353,097. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Price Performance

NYSE:ABT opened at $87.72 on Friday. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The firm has a market cap of $152.79 billion, a price-to-earnings ratio of 24.57, a P/E/G ratio of 1.47 and a beta of 0.65. The firm’s 50-day simple moving average is $97.19 and its 200 day simple moving average is $112.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period last year, the firm earned $1.09 earnings per share. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ABT. JPMorgan Chase & Co. lowered their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Evercore dropped their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. TD Cowen dropped their price objective on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. The Goldman Sachs Group dropped their price objective on shares of Abbott Laboratories from $140.00 to $121.00 and set a “buy” rating on the stock in a research report on Wednesday, April 8th. Finally, Bank of America dropped their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.